Cardiotrophin-1 as a prognostic biomarker of cardiovascular complications in comorbid patients with hypertension and concomitant type 2 diabetes mellitus and obesity

Abstract

Background. Since cardiovascular diseases (CVD) still occupy a leading place in the structure of mortality, the study of biomarkers that can be key in the diagnosis of early signs of the development of cardiovascular pathology continues. One such promising molecule is cardiotrophin-1 (CTF-1). The purpose of this study is to determinate of the circulating level of CTF-1 in comorbid patients with hypertension, and comparative analysis of its serum concentration in the presence of various comorbidities. Materials and methods. 111 patients with hypertension (men/women - 50/61) aged 54.37±1.18 and 20 persons of the control group were examined. In the process of careful examination and supervision of patients, they were divided into 4 groups depending on the presence of comorbid pathology in them: patients with AH- group 1 - 22 people; patients with AH + OB - group 2 - 30 people; AH+T2DM – group 3 – 31 people; patients with AH+T2DM + OB - group 4 - 28 people. Results. A direct correlation of CTF-1 level with weight, BMI, glycated hemoglobin level, SBP and DBP was established (p<0.001). The data we obtained prove that CTF-1 can be a trigger for the occurrence of cardiovascular complications, since its level progressively increases with increasing severity of comorbid pathology, and its highest serum concentration is found in patients with hypertension with concomitant T2DM and obesity. Conclusions. The level of CTF-1 was significantly higher in patients with AH, T2DM, OB compared to patients with AH, patients with AH and OB, as well as with this indicator in the control group. The study of the relationship between the serum level of CTF-1 and metabolic and hormonal indicators in comorbid patients is a promising direction for further research.